tfeb activator 1 Search Results


tfeb activator 1  (MedChemExpress)
94
MedChemExpress tfeb activator 1
BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB <t>activator</t> <t>1</t> (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.
Tfeb Activator 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tfeb+activator+1/TFEB+activator+1/pmc13216193-57-12-19
Average 94 stars, based on 1 article reviews
tfeb activator 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
tfeb activator 1 c1  (TargetMol)
93
TargetMol tfeb activator 1 c1
BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB <t>activator</t> <t>1</t> (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.
Tfeb Activator 1 C1, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tfeb+activator+1/TFEB+activator+1/pmc12848297-243-7-13
Average 93 stars, based on 1 article reviews
tfeb activator 1 c1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB activator 1 (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.

Journal: Frontiers in Pharmacology

Article Title: Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation

doi: 10.3389/fphar.2026.1763828

Figure Lengend Snippet: BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB activator 1 (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.

Article Snippet: Sorafenib (HY-10201), Baflomycin A1 (HY-100558), chloroquine (HY-17589A), rapamycin (AY-22989), resveratrol (HY-16561), and TFEB activator 1 (HY-135825) were purchased from MedChemExpress (Princeton, NJ, USA).

Techniques: Western Blot, Immunofluorescence, Staining, Binding Assay

SIRT1 activation rescues BBM-induced autophagy blockade. (A,B) Western blot analysis of SIRT1, TFEB, lysosomal proteins (CTSB, CTSD, RAB7), and autophagy flux markers (p62, LC3) in cells treated with BBM (5 μM) in the presence or absence of the SIRT1 agonist Resveratrol (Res, 10 μM) or the TFEB agonist TFEB activator 1 (0.5 μM) for 24 h. Data are presented as mean ± SD (n = 3). * p < 0.05, ** p < 0.01 vs. control; # p < 0.05, ## p < 0.01 vs. BBM-only group.

Journal: Frontiers in Pharmacology

Article Title: Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation

doi: 10.3389/fphar.2026.1763828

Figure Lengend Snippet: SIRT1 activation rescues BBM-induced autophagy blockade. (A,B) Western blot analysis of SIRT1, TFEB, lysosomal proteins (CTSB, CTSD, RAB7), and autophagy flux markers (p62, LC3) in cells treated with BBM (5 μM) in the presence or absence of the SIRT1 agonist Resveratrol (Res, 10 μM) or the TFEB agonist TFEB activator 1 (0.5 μM) for 24 h. Data are presented as mean ± SD (n = 3). * p < 0.05, ** p < 0.01 vs. control; # p < 0.05, ## p < 0.01 vs. BBM-only group.

Article Snippet: Sorafenib (HY-10201), Baflomycin A1 (HY-100558), chloroquine (HY-17589A), rapamycin (AY-22989), resveratrol (HY-16561), and TFEB activator 1 (HY-135825) were purchased from MedChemExpress (Princeton, NJ, USA).

Techniques: Activation Assay, Western Blot, Control